DUBLIN & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism exploited by cancer cells to evade the immune system, today announced that it will be presenting data from its ongoing ALX148 phase 1 clinical program at the SITC 32nd Annual Meeting, Nov. 8-12, 2017 in National Harbor, Maryland.
Poster Presentation Information
Title: A First-in-Human Study of ALX148: CD47 Blockade to Enhance Innate and Adaptive Immunity for Advanced Solid Tumor Malignancy and Non Hodgkin Lymphoma
Category: Clinical Trials (In Progress)
Date: Friday, November 10, 2017
Time: 12:30 p.m. – 2 p.m. and 6:30 p.m. – 8 p.m.
Abstract Number: P241
About Alexo Therapeutics
Alexo Therapeutics is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism exploited by cancer cells to evade the immune system. Our lead candidate, ALX148, is a fusion protein that comprises an engineered high affinity CD47 binding domain of SIRPa linked to an inactive Fc region of human immunoglobulin. ALX148 is designed to enhance the efficacy of antibody-based therapies and is in clinical development for a broad range of tumor types. www.alexotherapeutics.com
MacDougall Biomedical Communications
Karen Sharma or Shai Biran, Ph.D., 781-235-3060
alexo@macbiocom.com
